Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
Rhea-AI Summary
Verrica Pharmaceuticals (Nasdaq: VRCA) will report first-quarter 2026 financial results and provide a corporate update on Tuesday, May 12, 2026 at 4:30 p.m. ET.
The company will host a conference call and live webcast; domestic and international dial-in numbers and a conference ID (VERRICA) are provided. A webcast replay will be archived on Verrica's investor website for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – VRCA
In the May 5 session, VRCA gained 12.58%, reflecting a significant positive market reaction. Argus tracked a peak move of +28.0% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. Trading volume was very high at 4.9x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Earnings date set | Neutral | -2.4% | Announcement of Q4 and full-year 2025 results call and webcast timing. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date scheduling headline was followed by a modest negative move, showing markets can re-position around these reminders.
Recent news shows VRCA balancing commercial execution and investor outreach. On Mar 11, 2026, full-year 2025 results highlighted strong YCANTH growth and cost reductions. An earlier earnings date release on Mar 5, 2026 simply scheduled that call and coincided with a modest share decline. Today’s announcement similarly sets the timetable for Q1 2026 results and a corporate update, fitting into VRCA’s pattern of pre-announcing earnings events rather than introducing new financial metrics.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 12, 2026, to discuss the Company's financial results for the first quarter ending March 31, 2026, and provide a corporate update.
Individuals may participate in the live call via telephone by dialing 1-833-316-2483 (domestic) or 1-785-838-9284 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register.
A live audio webcast of the call can also be accessed by visiting the investor relations section of the Company’s website, www.verrica.com, or by clicking here. A replay of the webcast will be archived on Verrica’s website for 90 days following the event.
About Verrica Pharmaceuticals Inc.
Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
